Sun Pharmaceutical Industries Ltd

Profit before tax were at Rs 4,227.16 crore in Q3 FY26, up 21.59% as against Rs 3,476.4 crore in Q3 FY25. Formulation sales in India were Rs 49,98.59 crore, registering a growth of 16.2%. India Formulation sales accounted for 32.3% of total consolidated sales. Formulation sales in the US were $477 million, marginally up by 0.6%. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 27.5% of total consolidated sales. Emerging Markets formulations sales were $337 million, up by 21.6% and accounted for 19.4% of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $296 million, up by 14.5% and accounted for 17.1% of total consolidated sales. Global Innovative Medicines sales were $423 million for Q3 FY26. This included a milestone income of $55 million. Ex-milestone, Global Innovative Medicines sales were up 13.2% and accounted for 21.2% of sales. For Q3 FY26, external sales of API were Rs 541.2 crore, down by 4.7%. Sun Pharma's R&D efforts span both innovative and generic businesses, and the company continues to invest in building a robust pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in the clinical stage. The company has a comprehensive product offering in the US market, consisting of 550 approved ANDAs, while 116 ANDA filings await US FDA approval, including 28 tentative approvals. During the quarter, two ANDAs were filed, and two ANDAs received approval. Sun's portfolio includes 57 approved NDAs, while 14 NDAs are currently pending approval from the US FDA. The company declared an interim dividend of Rs 11 per equity share of Re 1 each for the financial year 2025'26. As intimated on 20 January 2026, the record date for determining entitlement to the interim dividend is 05 February 2026. The interim dividend shall be paid on or before 16 February 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India.Powered by Capital Market - Live

The benchmark equity indices began Sunday's session on a mixed footing in early trade, with the Sensex edging higher and the Nifty slipping marginally, as markets turned cautious ahead of the Union Budget 2026. The Nifty hovered around the 25,300 mark in early trade. Investors are gearing up for the release of the Union Budget 2026-27 today. Apart from sectoral announcements, all eyes would be on the growth projections and the fiscal deficit numbers that would be laid out by the Central Government today. Meanwhile, traders are also closely monitoring movements in the rupee, the flow of Q3 corporate earnings, and shifting geopolitical developments, all of which could influence near-term market sentiment. Metal, PSU bank and IT shares leading the fall while auto, private bank and pharma stocks advanced. At 09:25 IST, the barometer index, the S&P BSE Sensex advanced 28.66 points or 0.03% to 82,298.44. The Nifty 50 index fell 18.25 points or 0.07% to 25,306. In the broader market, the BSE 150 Mid-Cap index fell 0.77% and the BSE 250 Small-Cap index declined 0.72%. The market breadth was positive. On the BSE, 1,566 shares rose and 1,442 shares fell. A total of 164 shares were unchanged. Foreign portfolio investors (FPIs) had bought shares worth Rs 2,251.37 crore, while domestic institutional investors (DIIs) were net sellers to the tune of Rs 601.03 crore in the Indian equity market on 29 January 2026, provisional data showed. Numbers to Track: The yield on India's 10-year benchmark federal paper remain unchanged at 6.695 In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 91.9350 compared with its close of 91.9950 during the previous trading session. MCX Gold futures for 5 February 2026 settlement tumbled 9% to Rs 1,36,185. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.74% to 96.99. The United States 10-year bond yield advanced 0.33% to 4.241. In the commodities market, Brent crude for March 2026 settlement advanced 23 cents or 0.33% to $69.82 a barrel. Stocks in Spotlight: Sun Pharmaceutical Industries rallied 3.13% after the company has reported a 16.03% rise in consolidated net profit to Rs 3,368.81 crore on a 13.49% increase in revenue to Rs 15,520.54 crore in Q3 FY26 over Q3 FY25. Bajaj Auto added 1.65% after the company's standalone net profit increased 18.68% to Rs 2,502.81 crore on an 18.84% jump in revenue from operations to Rs 15,220.33 crore in Q3 FY26 over Q3 FY25. AstraZeneca Pharma India shed 0.08%. The company said it has received approval from the CDSCO to import, sell, and distribute Durvalumab (Imfinzi) solution for infusion in 120 mg/2.4 mL and 500 mg/10 mL strengths. Global Markets: On Friday, stocks witnessed some profit taking, with technology shares remaining in a funk, even as investors largely approved of President Donald Trump's pick of Kevin Warsh to lead the Federal Reserve. The S&P 500 fell 0.43% to finish at 6,939.03, its third straight down day. The Dow Jones Industrial Average pulled back 179 points, or 0.36%, to settle at 48,892.47. The tech-heavy Nasdaq Composite underperformed, dropping 0.94%, to end the day at 23,461.82. All three indexes fell more than 1% at session lows. Spot gold and silver dropped around 9% and 28%, respectively. Over the past year, gold and silver futures have soared about 67% and 142%, respectively. Warsh's selection was likely to ease concern about Fed independence because of his experience as a Fed governor and strong stance at times against inflation. While he is likely to push for lower rates in short term as Trump wants, the financial markets view him as someone who wouldn't always follow the president's direction and maintain credibility for monetary policy.Powered by Capital Market - Live

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 31 January 2026, inter alia, have recommended the interim dividend of Rs 11 per equity Share (i.e. 1100%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Profit before tax were at Rs 4,227.16 crore in Q3 FY26, up 21.59% as against Rs 3,476.4 crore in Q3 FY25. Formulation sales in India were Rs 49,98.59 crore, registering a growth of 16.2%. India Formulation sales accounted for 32.3% of total consolidated sales. Formulation sales in the US were $477 million, marginally up by 0.6%. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 27.5% of total consolidated sales. Emerging Markets formulations sales were $337 million, up by 21.6% and accounted for 19.4% of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $296 million, up by 14.5% and accounted for 17.1% of total consolidated sales. Global Innovative Medicines sales were $423 million for Q3 FY26. This included a milestone income of $55 million. Ex-milestone, Global Innovative Medicines sales were up 13.2% and accounted for 21.2% of sales. For Q3 FY26, external sales of API were Rs 541.2 crore, down by 4.7%. Sun Pharma's R&D efforts span both innovative and generic businesses, and the company continues to invest in building a robust pipeline for various markets. Sun's innovative R&D pipeline includes five novel entities in the clinical stage. The company has a comprehensive product offering in the US market, consisting of 550 approved ANDAs, while 116 ANDA filings await US FDA approval, including 28 tentative approvals. During the quarter, two ANDAs were filed, and two ANDAs received approval. Sun's portfolio includes 57 approved NDAs, while 14 NDAs are currently pending approval from the US FDA. The company declared an interim dividend of Rs 11 per equity share of Re 1 each for the financial year 2025'26. As intimated on 20 January 2026, the record date for determining entitlement to the interim dividend is 05 February 2026. The interim dividend shall be paid on or before 16 February 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. Shares of Sun Pharmaceutical rose 0.36% to Rs 1,595 on Friday, 30 January 2026. Powered by Capital Market - Live

Net profit of Sun Pharmaceutical Industries rose 16.03% to Rs 3368.81 crore in the quarter ended December 2025 as against Rs 2903.38 crore during the previous quarter ended December 2024. Sales rose 15.12% to Rs 15469.07 crore in the quarter ended December 2025 as against Rs 13436.94 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales15469.0713436.94 15 OPM %31.9929.84 - PBDT5448.974423.13 23 PBT4716.643792.57 24 NP3368.812903.38 16 Powered by Capital Market - Live

Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity. Sun Pharma will launch generic semaglutide injection under the brand name, Noveltreat, after the expiry of semaglutide patent in India. The product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly. The product is administered via an easy-to-use prefilled pen, designed to support convenient and accurate dosing. 'Obesity and diabetes have emerged as two of the most pressing health challenges confronting India and GLP-1 based therapies can play a meaningful role in addressing this growing burden. Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management. As India's largest pharmaceutical company with leadership in cardiometabolic therapies, we are committed to improving access to generic semaglutide across the country after the patent expiry', said Kirti Ganorkar, Managing Director, Sun Pharma. 'GLP-1 receptor agonists like semaglutide are an important scientific advancement for overall metabolic health, not just weight. These treatments should be combined with appropriate lifestyle measures such as diet and physical activity. They should be taken under close medical supervision. We are seeing growing patient interest in this therapy, and improved accessibility will help address unmet needs', said Dr. Unnikrishnan A G, Chief Endocrinologist and CEO, Chellaram Diabetes Institute. In December 2025, Sun Pharma received DCGI approval for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name Sematrinity, after the expiry of semaglutide patent in India.Powered by Capital Market - Live

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 January 2026.Powered by Capital Market - Live

Sun Pharmaceutical Industries has fixed 05 February 2026 as record date for payment of interim dividend, if declared. Powered by Capital Market - Live

Zen Technologies Ltd, Bharti Hexacom Ltd, HDFC Asset Management Company Ltd, CG Power & Industrial Solutions Ltd are among the other stocks to see a surge in volumes on BSE today, 16 January 2026.Sun Pharmaceutical Industries Ltd saw volume of 10.12 lakh shares by 10:46 IST on BSE, a 9.33 fold spurt over two-week average daily volume of 1.08 lakh shares. The stock dropped 1.03% to Rs.1,683.00. Volumes stood at 89093 shares in the last session.Zen Technologies Ltd clocked volume of 2.79 lakh shares by 10:46 IST on BSE, a 8.53 times surge over two-week average daily volume of 32722 shares. The stock gained 8.09% to Rs.1,327.85. Volumes stood at 34570 shares in the last session.Bharti Hexacom Ltd recorded volume of 3.06 lakh shares by 10:46 IST on BSE, a 5.73 times surge over two-week average daily volume of 53492 shares. The stock lost 1.93% to Rs.1,607.60. Volumes stood at 2.59 lakh shares in the last session.HDFC Asset Management Company Ltd saw volume of 2.53 lakh shares by 10:46 IST on BSE, a 4.58 fold spurt over two-week average daily volume of 55278 shares. The stock increased 3.97% to Rs.2,656.10. Volumes stood at 1.94 lakh shares in the last session.CG Power & Industrial Solutions Ltd witnessed volume of 10.8 lakh shares by 10:46 IST on BSE, a 4.58 times surge over two-week average daily volume of 2.36 lakh shares. The stock dropped 0.30% to Rs.575.20. Volumes stood at 1.29 lakh shares in the last session.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1761, up 0.05% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 26083.25. The Sensex is at 84758.67, down 0.36%. Sun Pharmaceutical Industries Ltd has dropped around 1.96% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has dropped around 2.31% in last one month and is currently quoting at 23126.85, up 0.16% on the day. The volume in the stock stood at 17.39 lakh shares today, compared to the daily average of 18.59 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1769.3, up 0.23% on the day. Sun Pharmaceutical Industries Ltd is down 4.18% in last one year as compared to a 10.11% gain in NIFTY and a 0.66% gain in the Nifty Pharma index.The PE of the stock is 90.36 based on TTM earnings ending September 25.Powered by Capital Market - Live